The FDA on Dec. 12 granted an accelerated approval to Mirati Therapeutics’ Krazati for the treatment of KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients that have received at least one other systemic therapy. The KRAS inhibitor, Mirati’s first commercial product, will face off against Amgen’s blockbuster-hopeful Lumakras, which gained approval in May 2021. Lumakras was the first KRAS inhibitor on the market, and currently holds covered or better status for 94% of all insured lives under the pharmacy benefit for the treatment of KRAS-mutated NSCLC. About 15.5% of covered lives have preferred access to Lumakras.
SOURCE: MMIT Analytics, as of 12/14/22